ERBB2 and breast cancer: Moreover, patients should be affected by either PD-L1 negative/BRCA-wild type TNBC or BRCA-wild type HR+/HER2-negative BC, where immunotherapy-based combinations and PARP inhibitors are not viable options (Figure 2).